Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024

Rhea-AI Summary

Lumos Pharma (NASDAQ:LUMO) announced that two abstracts featuring analyses from their Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting (ESPE 2024). The presentations, scheduled for November 17-18, 2024 in Liverpool, UK, will focus on LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD). The abstracts will cover growth responses and hormone secretion patterns in PGHD patients over 12-24 months of treatment.

AUSTIN, Texas, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that updated analyses of data from the Company’s Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted for oral presentation at the 62nd Annual European Society for Paediatric Endocrinology Meeting, or ESPE 2024, to be held November 16-18, 2024 in Liverpool, UK.

Two abstracts on data from the OraGrowtH Trials evaluating oral LUM-201 for Pediatric Growth Hormone Deficiency (PGHD) will be presented on Sunday, November 17^th, by Elżbieta Petriczko, MD, PhD, Pomeranian Medical University, Szczecin, Poland, and on Monday, November 18^th, by Peter E. Clayton, MD, University of Manchester, Manchester, UK, respectively.

LUM-201 Oral Abstract Presentations:

Sunday, November 17^th – Session: Free Communications 7: GH and IGFs – 10:50AM Local Time

• FC7.6 Abstract entitled, Growth, IGF-1 and IGFBP-3 Responses to Oral LUM-201 in OraGrowtH210 and OraGrowtH212 Trials in Pediatric Growth Hormone Deficiency (PGHD) Over 12 to 24 Months on Treatment (Elżbieta Petriczko, MD, PhD, et al)
  

Monday, November 18^th – Session: Free Communications 15: Late Breaking – 9:40AM Local Time

• FC15.2 Abstract entitled, Amount and Pattern of Pulsatile GH Secretion Induced by the Oral Growth Hormone Secretagogue LUM-201 Is Related to Growth and IGF-1 Responses in Moderate Pediatric Growth Hormone Deficiency (PGHD) (Peter E. Clayton, MD, et al)
  

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$4.7B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

When will Lumos Pharma (LUMO) present their OraGrowtH clinical trial data at ESPE 2024?

Lumos Pharma will present two abstracts at ESPE 2024 on November 17th and 18th, 2024, in Liverpool, UK.

What are the Phase 2 clinical trials of Lumos Pharma (LUMO) evaluating?

The OraGrowtH210 and OraGrowtH212 Phase 2 clinical trials are evaluating LUM-201, an oral treatment for Pediatric Growth Hormone Deficiency (PGHD).

Who will present the Lumos Pharma (LUMO) clinical trial data at ESPE 2024?

Dr. Elżbieta Petriczko from Pomeranian Medical University will present on November 17th, and Dr. Peter E. Clayton from University of Manchester will present on November 18th.